Barclays Raises Price Target for Oruka Therapeutics Stock to $50

Oruka Therapeutics (NASDAQ:ORKA) has received an optimistic forecast from Barclays, which increased its price target for the company’s stock from $48.00 to $50.00. This adjustment, communicated in a research note to investors on March 15, 2024, aligns with Barclays’ “overweight” rating for the stock, suggesting a potential upside of 25.41% based on the company’s previous closing price.

Analysts Weigh In

Other financial analysts have also recently reviewed Oruka Therapeutics. Stifel Nicolaus raised its price target significantly from $47.00 to $72.00, maintaining a “buy” rating. On December 18, Piper Sandler initiated coverage with an “overweight” designation and a target price of $75.00. Furthermore, UBS Group began coverage on January 7, issuing a “buy” rating alongside a $50.00 target.

Despite the positive outlook from several firms, Wall Street Zen downgraded Oruka Therapeutics from a “hold” to a “sell” rating on March 8. In contrast, Wedbush reaffirmed its “outperform” rating with a target price of $45.00. Currently, nine analysts have rated the stock as a Buy, while one has issued a Sell rating. According to MarketBeat.com, Oruka Therapeutics holds an average rating of “Moderate Buy” with a consensus target price of $56.67.

Quarterly Performance and Insider Activity

On March 12, 2024, Oruka Therapeutics reported its quarterly earnings, revealing an earnings per share (EPS) of ($0.45), exceeding analysts’ expectations of ($0.61) by $0.16. Analysts predict that the company will post an EPS of ($3.41) for the current fiscal year.

In insider news, Joana Goncalves sold 7,000 shares of Oruka Therapeutics on February 17, at an average price of $32.37, totaling $226,590.00. Following this sale, Goncalves retains 34,018 shares, valued at approximately $1,101,162.66, reflecting a 17.07% decrease in ownership. This transaction was disclosed in a legal filing with the SEC.

Over the past three months, insiders have sold a total of 21,000 shares worth $663,530, while company insiders currently own 24.69% of the stock.

Institutional Investment Trends

Several hedge funds and institutional investors have altered their positions in Oruka Therapeutics recently. Caitong International Asset Management Co. Ltd acquired a new stake during the fourth quarter, amounting to $67,000. Additionally, Seven Fleet Capital Management LP invested approximately $159,000 in the same period. Invesco Ltd. significantly increased its stake by 777.1%, now holding 143,121 shares valued at $4,338,000 after acquiring an additional 126,803 shares.

Virtus Investment Advisers LLC also purchased a new stake valued at around $267,000. RTW Investments LP lifted its holdings by 5.8%, now owning 2,058,148 shares worth $62,382,000. Approximately 56.44% of Oruka Therapeutics stock is currently held by hedge funds and institutional investors.

Recent Positive Developments

Several recent updates have positively impacted Oruka Therapeutics. BTIG reiterated a “buy” rating, increasing its price target to $73.00, indicating an upside of about 84.6% compared to the stock’s last close. Stifel Nicolaus’ endorsement with a $72.00 target adds momentum to the company’s appeal.

Guggenheim maintained a “buy” rating with a target of $60.00 (approximately 52% upside), while Wedbush’s $45.00 target represents a 14% upside. These endorsements strengthen the overall sentiment surrounding Oruka, particularly following its recent Q4 results, which beat consensus estimates and alleviated some near-term execution risks.

Moreover, Oruka Therapeutics anticipates results from its ORKA-001 EVERLAST-A 16-week data in the second quarter of 2026, following rapid enrollment. This accelerated timeline reduces risk and clarifies upcoming clinical catalysts.

Oruka Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative peptide-based therapies for oncology. Their proprietary stapled peptide platform aims to disrupt protein-protein interactions that contribute to tumor growth and immune evasion, targeting pathways previously deemed “undruggable.” The lead candidate, ONCT-01, is currently undergoing Phase 1 clinical trials focusing on safety, tolerability, and preliminary efficacy.